Mild to moderate COPD COPD
Conditions
Interventions
Triple therapy group: Inhale 100 ug of fluticasone, 62.5 ug of umeclidinium and 25 ug of vilanterol once daily for 24 weeks with an ellipta inhaler.
Combination therapy group: Inhale 62.5 ug of umecli
Sponsors
Hiromasa Inoue
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.40 years old and over 2.Mild to moderate COPD 3.Impairments of QOL (>=7 points of total COPD assessment test [CAT] score). 4.Airflow obstruction 50% assessed by Japanese Respiratory Society (JRS) criteria [32, 33] after administration of short-acting beta2 agonist (SABA). 5.Patients without a history of severe exacerbations in the last 12 months. 6.Prescription of LAMA or LABA alone monotherapy, or treatment naive Gender and smoking history do not matter. Non-smokers, passive smokers, former smokers and current smokers can all be registered.
Exclusion criteria
Exclusion criteria: 1.Women of childbearing potential. This includes women who are pregnant or lactating or are planning on becoming pregnant during the study. 2.Patients with a current diagnosis of asthma. (However, those patients with a prior history of asthma are eligible if they have a current diagnosis of COPD, and patients with ACO-like features, namely those whose condition will be partially met to the conditions defined for ACO in JRS guidance, may be included.) 3.Patients who cannot perform lung function tests 4.Patients who had acute respiratory tract infection (e.g. pneumonia) or moderate/severe COPD exacerbation within 4 weeks at the screening 5.Severe or unstable other comorbid diseases 6.Active respiratory infections or malignancies 7.Other chronic respiratory diseases (bronchiectasis, interstitial pneumonias, pneumoconiosis) 8.Patients who cannot use any inhalation devices 9.Past history of severe side effects or history of allergy/hypersensitivity to any corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the investigator contraindicates study participation.(Contraindications to the use of each drug follow the package inserts.) 10. Patients taking any investigational drug/ clinical study drug treatment within 30 days prior to Visit 1(Screening). 11.Patients who are recognized as inappropriate subjects in the study by physicians (eg, dementia, psychological disorders, cerebrovascular diseases with palsy, etc), because we will get informed consents by patients themselves and will not set other gardiners or proxies for informed consents. 12. Patients who are judged to be inappropriate by the investigator or sub-investigator based on the package insert of the target drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Average change in trough FEV1 after 12 weeks of treatment from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Subjects who improve by 2 points or more or 4 points or more after 24 weeks of treatment using the minimum clinically significant change in the CAT score or the total score of SGRQ are considered to be effective patients (effective persons). Find out the percentage of effective persons. | — |
Contacts
Public ContactTakahashi Koichiro
Saga University Hospital
Outcome results
None listed